Abstract 441P
Background
To evaluate the effectiveness of radiation therapy (RT) in patients with somatotropic pituitary adenomas, depending on the age of patients and the activity of pituitary adenomas.
Methods
The subject of the study were 50 patients (women-36, men-14) with acromegaly who received gammatherapy in a total dose of 45-60Gr of 20-25fractions every other day. The duration of the disease was 15years on average. In general, the age of patients ranged from 26 to 77years, on average-44.7±6.8years. By age, the patients were divided into 3 groups: the I age group-29-44years-23patients (46%), the IIgroup-45-59year-16patients (32%), the IIIgroup-60-79years, 11patients (22%). All patients underwent hormonal (GH, IGF-1) studies.
Results
The levels of hormones of GH and IGF-1 remained high in the I group in 22% of patients, and in group III in 9%. Remissions reached 64% in the III age group. The highest level of GH content occurred in the age range from45 to59years and was 77.5±9.68mMе/l, and from 26 to 44years it was 68.1±6.84mMе/l. After RT, this indicator in both age groups was almost equally suppressed, but not up to the norm. The decrease in the GH level to normal was observed in I age group in 8patients, and in the II age group in 5patients it was 2.65±2.2mMе/l and 2.23±1.4mMе/l, respectively. In group III, in 11 patients before RT, the mean level of GH was 46.5±8.2mMе/l. After RT, the level of GH decreased in this way: not suppressed only in one patient and was 22.1±0.89mMе/l, in 3patients the level of GH was suppressed, but not up to the norm and amounted to6.7±0.7mMe/l, only 7patients were suppressed and amounted to 2.46±2.2mMe/l.
Conclusions
In all age periods, even in the period of the most activity pituitary adenoma-at the age of 26-44 years, RT is a rather effective method of treatment and gives positive results in most cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session